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Summary.-The carcinogenicity of250 chemicals in 2 species, usually the rat and the
mouse, was obtained from the published literature through 3 independent sources.
Of the 250 compounds listed, 38% were non-carcinogenic in both rats and mice, and
440O were carcinogenic in both species. A total of43 compounds had different results
in the two species, 21 (8%) being carcinogenic in mice only, 17 (70o) in rats only and
5 (2%) having differing results from other species. A comparison of the major target
organs affected by chemicals carcinogenic in both species revealed that 64% of the
chemicals studied produced cancer at the same site.
This comparison of carcinogenic activity in 2 species suggests that extrapolation
from results in a single-animal study to man may be subject to substantial errors.
THE RECENT INTEREST in short-term
tests for carcinogenicity has focused
attention on the predictability of such
tests for carcinogenicity as defined by
animal studies. Several studies have been
undertaken to establish the correlation
between short-term test results and animal
carcinogenicity (McCann et al., 1975;
Purchase et al., 1978). The test systems
with the best results (Salmonella micro-
some assay and cell transformation assay)
have correlations with each other and with
animal studies of between 85 and 950.
Some reasons for the lack of 100% correla-
tion with animal data, i.e. the false
negatives and false positives, can be found
in the design and execution of either the
animal or the short-term tests. In addition,
differences in the end-point or differences
in metabolism, diffusion and transport
barriers and the state of the cellular tar-
gets in the two types of test system may
contribute to the anomalies generated by
the various methods. It is thus not sur-
prising that chemicals can produce effects
in in vitro tests, with their imposed arti-
ficiality, which will not be seen in vivo.
Also, depending on the criteria used to
judge the results of animal carcinogenicity
studies, the classification of chemicals as
carcinogens or non-carcinogens affects the
correlation.
It is conventional to place greater
reliance on extrapolating results to man
from the results from tvpical long-term
in vivo studies in mammals than from in
vitro studies using mammalian cells or
unicellular organisms. The reason for this
is partly the differences in end-points
described above, but it also derives from a
greater experience with mammalian car-
cinogenicity studies and the greater
apparent relevance ofthe tumours genera-
ted in animal studies as a model of car-
cinogenicity in man. These arguments are
not based on systematic study, and there-
fore provoke the questioni, "Is the reliance
on animal carcinogenicity models war-
ranted?"
Differences in the expression of car-
cinogenic effects between mammalian
species do occur, and these are due not
only to details ofexperimental design, but
also to critical differences between species.
It is apparent that extrapolation of sus-
ceptibility to chemical carcinogenicity
from animals to man is just one form of
inter-species comparison, and this hasINTER-SPECIES COMPARISONS OF CARCINOGENICITY
been studied mainly from the converse
point of view of demonstrating which
human carcinogens have proved to be
carcinogenic in animals (Tomatis et al.,
1978). This review compares carcinogeni-
city data from experiments in 2 species of
mammals (particularly rats and mice) as a
step towards understanding the relevance
of such data from one species when pre-
dicting the carcinogenicity of that com-
pound in a second species. A similar, but
smaller, review was carried out byTomatis
et al. in 1973.
METHODS
Source ofdata.-References and opinions on
carcinogenicity were obtained from three
sources:
(1) National Cancer Institute Bioassay Pro-
gramme. In this programme chemicals
have been tested in rats and mice using
similar protocols. For the purposes of this
comparisontheopinionsoncarcinogenicity
expressed in the reports of the results
appearing in the Federal Register have
been taken as definitive. Where equivocal
results are reported, these have been
omitted.
(2) International Agency for Research on
Cancer, Monograph Series (1972-1978).
The IARC have convened meetings of
experts to consider reports of carcino-
genicity and these include opinions on
carcinogenicity of chemicals to various
species. The opinions of the committees
have been accepted as definitive at the
times of the respective meetings, and no
attempt to revise the opinions has been
made. Chemicals which have been tested
adequately in at least 2 species have been
selected for inclusion.
(3) References to carcinogenicity studies were
obtained from U.S. Public Health Service
Document No. 149 (Hartwell & Shubik,
1951-1973). By reference to the index,
the chemicals which had been tested in
more than one species were identified.
The most comprehensive study in each
species was identified from Hartwell and
Shubik's summary tables. The data in the
original publication were examined ac-
cording to the "decision tree" described
below. If a positive effect was observed,
this was recorded; if the results were
negative, all relevant references were
examined and the result recorded. Refer-
ence to a single study is made in Appendix
3. Chemicals on which the carcinogenicity
had already been reported by the IARC
Committees were excluded from evalua-
tion.
Decision rules.-Afterselectionofthestudy,
the following idealized decision tree was used.
It should be noted thatin some cases decisions
were not as clear-cut as the decision tree
might indicate, and other criteria were used
to assist the decision.
(1) Check adequacy of histological examina-
tion.
(a) If Level 1 or 2 (Hartwell & Shubik,
1951), reject.
(b) If Level 3, proceed.
(2) Establish tumour incidence in treated and
control animals.
(a) If there is a significant increase in
treated animals, proceed to (3).
(b) If there is no increase in treated
animals, proceed to (6).
(3) Establish number ofanimals per group.
(a) Ifthere are less than 15, reject.
(b) If there are more than 15, proceed to
(4).
(4) Establish route ofadministration.
(a) If by repeated s.c. injection or bladder
implant, proceed to (5a).
(b) If other route, proceed to (5).
(5) Establish tumour type.
(a) If tumours are at the site of s.c.
injection (or in the bladder, in bladder
implantation studies) reject.
(b) If tumours are benign and there is a
high incidence in controls (e.g. pul-
monary adenoma or hepatoma in
certain strains of mice; mammary
fibroadenomas, adenomas or fibromas
or Leydig-cell tumours in certain
strains of rat) reject.
(c) If other tumours, classify as POSI-
TIVE.
(6) Establish number ofanimals per group.
(a) If there are less than 25, reject.
(b) If there are more than 25, proceed to
(7).
(7) Establish the length of the study.
(a) Ifless than 80 weeks in mice or 2 years
in rats, reject.
(b) If more than 80 weeks in mice or 2
years in rats, proceed to (8).
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TABLE I.-Summary of results from three different sources
Response in carcinogenicity
studies
-ve in rat andmouse
+ve in rat and mouse
Rat -ve, mouse +ve
Rat +ve, mouse -ve
Differing results from other species
Total
NCI IARC Other
(Appendix 1) (Appendix 2) (Appendix 3) Total (%)
26 8 64 98 (39)
26 60 23 109 (44)
13* 6 2 21 (84)
8 4 5 17 (6-8)
5t 5 (2)
73 83 94 250 (100)
* Excluding dieldrin, which is reported in Appendix 1. The IARC opinion was given before the NCI
bioassay was completed. Both opinions agree and the compound is included in the IARC column.
t These 5 compounds include hydrazine and thioacetamide (+ve in rat and mouse but -ve in hamster)
and arsenic (-ve in rat and mouse but considered a human carcinogen).
(8) Examine other aspects of the study, such
as abnormal diets, additional chemicals
used and unusual route ofadministration.
(a) Ifit invalidates the study, reject.
(b) If there is no problem identified, clas-
sify the compound as NEGATIVE.
Target organ.-The major target organ(s)
reported to be affected have been noted for
chemicals carcinogenic in 2 species.
RESULTS
The summarized results are presented
in Appendices 1, 2 and 3. All chemicals
reported in Hartwell & Shubik which were
tested in species other than the rat and
mouse had been reported in the IARC
Monographs. They were therefore not
included in Table II. The number of
chemicals selected from each ofthe 3 data
sources and the number found to give
various combinations ofresults in rats and
mice (and in 5 cases other species) is given
in Table I. Of the 250 compounds listed,
98 (38%) were negative in both rats and
mice, and 109 (44%) were positive in both
rats and mice. A total of 43 had different
results from the species tested, 21 (8%)
being carcinogenic in mice only, 17 (7%)
TABLE II.-Organ specificity of chemical
carcinogens
No. of chemicals
positive in rat
and mouse
NCI
IARC
Other
Total
26
60
23
109
No. of chemicals with
at least one common
site in both species
(%)
15 (58)
40 (67)
15 (65)
70 (64)
in rats only and 5 (2%) having results
from other species.
When a comparison is made ofthe major
target organs affected in both species, only
64% of chemicals are found to produce
cancer at the same site in both species
(Table II).
DISCUSSION
The most important reason for testing
chemicals for carcinogenicity is to provide
information on which an assessment of
potential human carcinogenicity can be
made. A judgment on the effectiveness of
the animal tests in identifying human
carcinogens could best be made by identi-
fying which human carcinogens are also
carcinogenic in animals. This is not very
satisfactory for two reasons: firstly, only
26 specific causes of human cancer have
been identified (of which only 19 can
be attributed to a single chemical;
Tomatis et al., 1978) so that few com-
parisons can be made. Secondly, most
human carcinogens were first identified by
clinical or epidemiological methods, and
subsequent animal experiments were de-
signedtofind asuitable modelforstudying
the carcinogenic effects. This approach is
substantially different from that oftesting
a compound of unknown activity. Never-
theless, there remain 2 compounds con-
sidered to be associated with the induction
of human cancer (Tomatis et al., 1978)
which have not been shown unequivocally
to be animal carcinogens, namely arsenic
and benzene.
In examining other inter-species com-
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parisonls of carcinogeniicity, certain prob-
lems must be recognized. Firstly, the
comparison is being made at a certain
time, and new data are continually being
produced which may alter the opinion on
a chemical's carcinogenicity. In order to
overcome this problem Hartwell and
Shubik's survey and the more up-to-date
IARC Monograph Series have been used to
provide certain of the data for this
review. Since the dates of publication of
these references' sources, new data may
have been produced on the carcinogenicity
of the chemicals. This has not been in-
cluded, except for that produced by the
NCI Bioassay Programme, which has been
tabulated separately. In most cases, chan-
ges of classification as a consequence of
new data on carcinogenicitv are from non-
carcinogen to carcinogen, because one
positive study is often more convincing
than several negative studies. These
changes in classification are likely to have
an effect on all the subdivisions of chemi-
cals used in Tables II and III, except
"carcinogenic in all species tested", but it
is not possible to estimate the magnitude
of the effect.
The second problem is that opinions and
interpretations of the same data on the
carcinogenicity of chemicals often differ.
To reduce the bias likely from this source,
several steps have been taken. The IARC
Monograph Series, being the opinions of
expert committees, are least likely to be
affected by bias. The NCJ Bioassay Pro-
gramme reports published in the Federal
Register are summaries of the data pre-
sented in the full reports, which have been
reviewed by the Data Evaluation/Risk
Assessment Subgroup of the Clearing-
house on Environmental Carcinogens (a
U.S. National CancerInstitutecommittee).
The opinion subject to the least review is
that expressed in Appendix 3 on the
chemicals selected from "Survey of chemi-
cals which have been tested for carcino-
genicity". The outline of the method used
to classify them is given in the methods
section.
The third problem is the difficulty of
being satisfied that a chemical is non-
carcinogenic on the basis ofanimal experi-
ments. It is always possible that higher
doses, longer survival, greater numbers of
dose groups or animals, different strains,
species or routes of administration or any
of the many factors affecting the outcome
of a carcinogenicity study will give a
positive result. The opinions of non-
carcinogenicity given in Table III refer to
the specific studies examined. Similarly,
the IARC and NCI reports confine them-
selves to statements such as, "under the
conditions of this study photodieldrin was
not carcinogenic to Osborn-Mendel rats
or B6C3F1 mice".
It is clear from the information obtained
from three separate sources that there are
a substantial number ofcompounds which,
although carcinogenic in one species, have
not been shown to be carcinogenic in a
second species. There are differences in the
number of chemicals falling into the
various categories depending on the source
of the data. Thus, very few chemicals
which are non-carcinogenic in 2 species
are seen in the IARC series, probably
reflecting the philosophy of selection of
chemicals for review. There are few chemi-
cals in Appendix 3 which are negative in
one species and positive in the second;
this is because most of the chemicals in
this category selected from the "Survey of
chemicals which have been tested for
carcinogenicity" had been reported on in
the IARC Monographs and were therefore
omitted from Appendix 3. For these
reasons the most significant figures are
those which combine the information from
all three sources. Of the 250 chemicals for
which data in 2 species are available, 109
(440%) were carcinogenic in both species,
98 (390o) were non-carcinogenic in both
species and 43 (17%) were carcinogenic
in one species and non-carcinogenic in the
other.
Another way ofexpressing this informa-
tion is that of 126 chemicals found to be
positive in the rat, 109 (87%) were positive
in the mouse; and of the 119 chemicals
found to be negative in the rat 98 (82%)
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were negative in the mouse. Similarly, of
the 130 chemicals found to be positive in
the mouse, 109 (84%) were positive in the
rat: and of the 115 chemicals negative in
the mouse 98 (85%) were negative in the
rat. This suggests that a chemical positive
in one species has about an 85% chance
of being positive in a second species. A
similar figure was obtained in the review
by Tomatis et al. (1973).
Cooper et al. (1979) have provided a
method of expressing the usefulness of
short-term tests for carcinogenicity which
involves calculation of the specificity and
sensitivity of a test. Similar calculations
can be made for these long-term animal
studies. As a predictor of carcinogenicity
in the mouse, the rat carcinogenicity study
has a specificity of85.2% and a sensitivity
of83 8%. The mouse carcinogenicity study
has a specificity of82.4% and a sensitivity
of 86.5% as a predictor of rat carcino-
genicity. These figures taken on their own
can be misleading, as the overallpredictive
value of a test result is also dependent on
the prevalence of carcinogens among the
chemicals tested. If the chemicals tested
had a 10% prevalence of carcinogens the
predictive value for both rat and mouse
results would be 27%.
The reasons for differences in carcino-
genicity and organ specificity between the
resultsinthe 2 species, whentheyoccurred,
are not readily apparent. Factors such as
differences in metabolism and metabolic
products may well contribute to these
differences. Where the route ofadministra-
tion has been different in the 2 species
tested, this may also contribute to dif-
ferences in response, though there are
many examples in Appendices 1, 2 and 3
where this is not so.
One important feature of the results
is that where differences in carcinogenicity
between 2 species are obtained, the chemi-
cals concerned may share certain struc-
tural characteristics. Thus, there are
several chlorinated pesticides which are
positive in mice but negative in rats;
1,],2-trichlorethane and 1,1,2,2-tetrachlor-
ethane are negative in rats but positive
in mice. In these cases metabolic pathways
and mechanisms of action may account
for the difference in response. As has been
suggested for short-term tests (Ashby &
Purchase, 1977) this may be a useful way
of improving extrapolation of results to
other species, particularly when appro-
priate positive and negative control data
are available to assist in the extrapolation.
Accurate extrapolation to man requires
an intimate knowledge of the metabolism
and mode of action of the chemical in the
species selected for laboratory tests and
knowledge of whether the key features
established in the laboratory animal are
also present in man.
In most cases, knowledge of the meta-
bolic fate of a chemical in man is imper-
fectly understood, and it is against this
background that extrapolation is fre-
quentlymade. Possiblytheonlyadditional
evidence that can be used in the extrapo-
lationisthelackofinter-speciesvariability
in laboratory tests (or consistency). Thus
a chemical carcinogenic in all species
tested and in all in vitro mutagenic assays
could be considered to be more likely to be
carcinogenic in an untested species. An-
other chemical, negative in all but one
test, would be less likely to be carcinogenic
in an untested species. Using this argu-
ment, N-nitrosodiethylamine, carcinogenic
in 8 species, is more likely to be carcino-
genic in man than isonicotinic acid hydra-
zide, which is carcinogenic in mice but
not in rats and hamsters. As in all simple
rules, there will be exceptions (e.g. 2-
naphthylamine, a potent carcinogen in
man, is carcinogenic in 3 laboratory
species but negative in rats and rabbits).
Nevertheless, information on the mode of
action, metabolism and pharmacokinetics,
and on the results from chemicals with
similar critical structural features, to-
gether with data on consistency, will pro-
vide a better basis for extrapolation than
the simple assumption that a carcinogenic
response in one species indicates carcino-
genic hazard in man.
I- thank Mrs N. Wilson for her assistance in
surveying the literature.
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APPENDIX 1
Summarized carcinogenicity resultsfrom NCI Bioassay Programme
1. Rat and mouse negative. p.o. administration
Compound
Anilazine
p-Anisidine hydrochloride
Anthranilic acid
IH-Benzotriazole
2-Chloro-p-phenylenediamine
sulphate
Chlorpropamide
3-Chloro-p-toluidine
Clonitralid'
Diarylanilide Yellow
Dichlorvos
Dimethoate
Dioxathion
lodoform
Lindane
Malathion
Methoxychlor
Mexacarbate
4-Nitroanthranilic acid
1-Nitro naphthalene
3-Nitro proprionic acid
1-Phenyl-3-methyl-5-pyrazolone
Photodieldrin
2,3,5,6-Tetrachloro-4-nitro-
anisole
Triphenyltin hydroxide
Tolbutamide
2,5-Toluenediamine sulphate
Federal
Register
Reference
4905543 (1978)
47793 43 (1978)
14130 43 (1978)
40061 43 (1978)
46382 43 (1978)
64444 42 (1977)
4957443 (1978)
47793 43 (1978)
11760 43 (1978)
43132 42 (1977)
15140 42 (1977)
45645 43 (1978)
46382 43 (1978)
58791 42 (1977)
12385 43 (1978)
11760 43 (1978)
4957443 (1978)
49055 43 (1978)
26139 43 (1978)
21737 43 (1978)
49055 43 (1978)
61316 42 (1977)
50741 43 (1978)
49574 43 (1978)
62212 42 (1977)
49055 43 (1978)
2. Rat and mouse positive. p.o. administration, except * (i.p.).
Compound
2-Aminoanthraquinone
3-Amino-9-ethylcarbazole
1-Amino-2-methylanthraquinone
0-Anisidine hydrochloride
Chlordecone
Chloroform
Site affected
Rat Mouse
Liver (m)
Liver
Liver, kidney (m)
Bladder, kidney (m),
thyroid (m)
Liver
Kidney
Liver
Liver
Liver (f)
Bladder
Liver
Liver
Federal Register
Reference
51451 43 (1978)
47289 43 (1978)
97289 43 (1978)
43074 43 (1978)
1491441 (1978)
23449 41 (1978)
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Site affected
Compound
3-(Chloromethyl)pyridine
hydrochloride
4-Chloro-m-phenylenediamine
4-Chloro-o-phenylenediamine
2,4-Diaminoanisole sulphate
Dibromochloropropane
1,2-Dichloroethane
1,4-Dioxane
Hydrazobenzene
*Isophosphamide
1,5-Naphthalenediamine
Nitriloacetic acid
NTS tri-sodium salt, monohydrate
Nitrofen
5-Nitroacenaphthene
5-Nitro-o-anisidine
Phenazopyridine HCI
Tetrachlorvinphos
4,4'-Thiodianiline
*Thio-tepa
Trimethylphosphate
Tris (2,3-dibromopropyl)phosphate
Rat
Stomach (m)
Adrenal glands (m)
Urinary bladder,
forestomach
Skin (associated
glands), thyroid
Stomach, mammary
gland (f)
Stomach, mammary
gland (f)
Liver (f), nasal
turbinates
Liver, Zymbal's
gland, mammary
gland
Uterus, mammary
gland (f)
Uterus, clitoral
gland (f)
Urinary tract
Pancreas (f)
Ear canal, lung,
clitoral and
mammary glands
(f)
Integumentary
system, clitoral
glands (f)
Colon
Thyroid, adrenal
gland
Thyroid, ear canal,
liver, colon (m),
uterus (f)
Skin, ear canal,
haemopoietic
system (m)
Subcutaneous
tissue (mi)2
Kidney
Mouse
Stomach
Liver (f)
Liver
Thyroid
Stomach
Mammary gland,
uterus, bronchi
Liver
Liver (f)
Haemopoietic
system (f)
Thyroid, liver,
lung (f)
Urinary tract
Liver
Liver, ovary (f)
Liver (f)
Liver (f)
Liver (f)2
Liver, thyroid
Skin, associated
glands
Uterus (f)
Liver, lung,
stomach (f),
kidney, lung,
stomach (m)
Federal Register
Reference
4728943 (1978)
39431 43 (1978)
30356 43 (1978)
16417 43 (1978)
8189 43 (1978)
4356443 (1978)
41285 43 (1978)
40548 43 (1978)
2942 43 (1978)
51451 43 (1978)
2553442 (1977)
885443 (1978)
50741 43 (1978)
4957443 (1978)
4564543 (1978)
12951 43 (1978)
2056243 (1978)
4307443 (1978)
42043 43 (1978)
19463 43 (1978)
3. Rat result negative; mouse positive. p.o. administration
Compound Rat
Aldrin
3-Amino-3-ethoxyacetanilide
Captan
Chloramben
Chlordane
Chlorbenzilate
Dicofol
Dieldrin4
Heptachlor
Hexachloroethane
5-Nitro-o-toluidine
1,1,2,2-Tetrachloroethane 2
1,1,2-Trichloroethane
Trifluralin
Mouse
(m)
(m)
(f)
(m)
(i)
(f)
Federal Register
Reference
2450 43 (1978)
40062 43 (1978)
5912042 (1977)
56805 42 (1977)
4839442 (1977)
47793 43 (1978)
4489043 (1978)
245043 (1978)
48395 42 (1977)
27238 43 (1978)
4307443 (1978)
9360 43 (1978)
30365 43 (1978)
12385 43 (1978)
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4. Rat result positive; mouse negative. p.o. administration
Compound
4-Amino-2-nitrophenol
Aniline hydrochloride
Chlorothalonil
m-Cresidine
Dapsone
2,4-Dinitrotoluene
Picloram
Pivalolactone
Rat
(m)
(m)
3
(f)3
Mouse
Federal Register
Reference
45645 43 (1978)
50741 43 (1978)
46382 43 (1978)
44890 43 (1978)
61631 42 (1977)
21737 43 (1978)
5076 43 (1978)
50741 43 (1978)
Abbreviations:
p.o.-administration by gavage or by addition to diet.
m-male.
f-female.
1-Negative in the female mouse; male not evaluated because of poor survival.
2-two hepatocellular carcinomas observed; not statistically significant.
3-benign tumours.
4-also included in the IARC tabulation.
Footnote
Most reports in the Federal Register up to 24 October 1978 have been examined. For various
reasons, such as inadequacy of the data or only one species being tested, the following compounds listed in
the Federal Register have not been included in the tabulation:
Aroclor 1254
5-Azacytidine
Chloropicrin
Diaminoxide
1,1-Dichloroethane
Emetine
Hexachlorophene
3,3'-Iminobis-l-propanol dimethane sulphonate
Lasiocarpine
2-Methyl-1-nitroanthraquinone
Phenformin
N-phenyl-p-phenylene diamine
Proflavin
Tetrachloroethvleno
1,1,1-Trichlorethane
Trichloroethylene
Trichlorofluoromethane
APPENDIX 2
Summarized data from IARC Monograph Series
1. Rat and mouse negative
Compound
Aniline
y-Butyrolactone
Cis-9, 10-
Epoxystearic acid
Maleic hydrazide
Norgesterol
Ponceau SX
Yellow AB
Yellow OB
Route
(rat)
P.O.
P.O.
s.c.
s.c.
P.O.
s.c.
P.O.
P.O.
s.c.
P.O.
s.c.
P.O.
s.c.
Route
(mouse) Reference
s.c. 27 4 (1974)
p.o. 231 11 (1976)
s.c.
s.c. 153 11 (1976)
top
p.o. 173 4 (1974)
s.c.
p.o. 201 6 (1974)
p.o. 207 8 (1975)
s.c.
279 8 (1975)
s.c.
287 8 (1975)
s.c.
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2. Rat and mouse positive
Compound
Amitrole
o-Aminoazotoluene
4-Aminobiphenyl
Aramite
Asbestos
Benzidine
Benzo(a)pyrene
N,N-bis(2-chloroethyl)-2-
naphthylamine
Bis(chloromethyl)ether
f-Butyrolactone
Cadmium salts
Carbon tetrachloride
Chlorambucil
Chromium salts
Calcium chromate
Citrus Red No. 2
Cycasin
Cyclophosphamide
Diazomethane
Dibenz(a,h)anthracene
7H-Dibenz(C1g) carbazole
l,2-Dibromo-3-
chloropropane
Diethylstilboestrol
Dihydrosafrole
1,2-Dimethylhydrazide
Ethinyloestradiol
Ethylene dibromide
Ethylmethane sulphonate
Ethynodiol diacetate
2[2-Formylhydrazino]-4-(5-
nitro-2-furyl)thiazole
Isosafrole
Melphalan
Rat
Route Site affected
S }Thyroid, liver
p.o. Liver, bladder
s.c. Mammary gland,
intestine
p.o. Liver
ihl Lung i.h. un
s.c. Liver
P.o. O
top.
i.t. LMammary gland,
i.v. forestomach
P.O.
s.c. Local tumours
S.C. }Lung, nasal cavities
s.C. \ Tumours at site of
p.o. f admin.
s.C. Interstitial-cell
tumours of testis
s.c. Liver
i.h.J
i.p. Lymphomas
i.b. Lung
p.o. Bladder
p.o. Liver, kidney
s.c. Lung, liver,
i.p. f reproductive organs
i.h. Lung
s.c.
i.t.
s.c.
}Lung
1 expt: sarcomas, no
details
p.o. Forestomach,
mammary gland
s.c. Mammary gland,
pituitary
P.O.
s.c.
P.O.
P.O.
Oesophagus
}Intestine, lung
Liver
p.o. Forestomach
i.p. Lung
p.o. Mammary gland
(benign) (m)
p.o. Mammary gland,
gastrointestinal
tract
p.o. Liver
i.p. Peritoneum
Mouse
Route Site affected
p.o. Thyroid, liver
i.p., -)
s.c., Liver, lung
P.o. J
p.o. Bladder, liver
p.o. In 1 of 4 strains
tested: liver
i.h. Lung
s.C. Liver
top.
i.p. Forestomach
P.o. J
i.p. Lung
s.c.
top. SLung 2
i.h. J
top. l Tumours at site
s.C. f of admin.
s.C. Interstitial-cell
tumours of testis
p.o. Liver
i.p. Ovary, lung
i.h. Lung
s.c. Bladder
tOP. Liver, lung, kidney I P.O.
ivp. Mammary gland
s.c.1
i.h. Lung
top.
top. Forestomach
P.O.
top.
s.C. Forestomach, liver
P.o. J
p.o. Forestomach
p.o. Mammary gland,
s.C. - cervix, vagina (f),
J testis (m)
p.o. Liver (m), lung
S.c. }Liver, lung, muscle
p.o. Pituitary, mammary
gland
p.o. Forestomach
S.p }Lung, kidney i.p.j
p.o. Mammary gland
(castrated) (m)
p.o. Stomach, lung
p.o. Liver
i.p. Lung
Reference
31 7 (1974)
61 8 (1975)
74 1 (1972)
39 5 (1974)
17 2 (1972);
142 (1977)
80 1 (1972)
91 3 (1975)
119 4 (1974)
31 4 (1974)
225 11 (1976)
74 2 (1973)
53 1 (1972)
125 9 (1975)
100 2 (1973)
101 81 (1975)
157 1 (1972)
135 9 (1975)
223 7 (1974)
178 3 (1973)
2603 (1973)
139 15 (1977)
55 6 (1974)
231 10 (1976)
145 4 (1974)
776 (1974)
195 15 (1977)
245 7 (1974)
173 6 (1974)
151 7 (1974)
231 10 (1976)
167 9 (1975)
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Rat Mouse
tK
A
,i r
A
--
Compounds
Mestranol
Methyl methanesulphonate
N-methyl-n-nitro-n-
nitrosoguanidine
Methylthiouracil
Metronidazole
Nickel salts
Nickel subsulphide
Nickel subsulphide,
nickel oxide
5-Nitroacenapthene
N-[4-(5-nitro-2-furyl)-2-
thiazolyl] acetamide
Nitrogen mustard
Nitrogen mustard n-oxide
hydrochloride
N-nitrosodiethylamine
N-nitrosodimethylamine
Nitrosoethylurea
Nitrosomethylurea
Norethisterone
Norethynodriel
Oestradiol 17f
Oestrone
Phenobarbitone
Ponceau MX
P-Propiolactone
Propylthiouracil
Safrole
Sterigmatocystin
Streptozotocin
Thiouracil
Uracil mustard
Urethane
Vinyl chloride
Route Affected organ
P.O.
l.p.
s.c.
i.p.
P.O.
Mammary gland (f)
Nervous system
Stomach, forestomach,
liver
}.C. Thyroid, kidney (f)
p.o. Mammary gland
i.h. Lung
i.m. Local tumours
p.o. Intestine, mammary
gland (f)
p.o. Mammary, salivary
glands, lung, renal
pelvis
i.v. Variety of tumours
i.v. Lymphoreticular
tumours
i.h.
i.p. tLiver
P.o. J
i.p. 1
i.h. Liver, kidney
p.o. J
s.c. 1
i.v. Brain, peripheral
p.o. J nervous system
top.
i.p. Brain, peripheral
i.v. nervous system
P.O. J
p.o. Liver (m) (benign)
p.o. Liver, pituitary
s.c. Mammary gland,
pituitary
s.c. Pituitary, mammary
gland
p.o. Liver, benign
p.o. Liver
p.o. Forestomach
p.o. Thyroid
p.o. Liver
top. Liver
P.O.
iv. Kidney, liver
i.p.
p.o. Thyroid
i.p. Peritoneum, pancreas,
ovary, mammary
gland
LP.} Liver, uterus etc. p.o.J
i.h. Liver, Zymbal
gland, kidney
Route Affected organ
p.o. Mammary gland,
pituitary
i.p. Lung; thymic
p.o. lymphomas
top.
i.p. Stomach
P.o. J
p.o. Thyroid
p.o. Lung
i.m.
l.p.
P.O.
Local tumours
Leukaemia, reticulum
cell sarcoma
Forestomach
s.c.
i.p. SLung, thymus
i.V. J
s.c. Lung, thymus,
Harderian gland
top.
i.p. Liver, forestomach,
s.c. oesophagus, lung
P.o. J
s.c.
i.p. Liver, lung
P.O.
i.p. Multiple tumours,
including intra-
cranial, neurogenic
top.
s.c. -Lung; thymic
i.p. J lymphomas
s.c. lLiver (m, benign)
p.o. fi pituitary (f)
S.c. Pituitary
P.O.J
s.c. Mammary gland,
pituitary, repro-
ductive system
s.C. Mammary gland
p.o.
p.o. Liver, benign/
malignant
p.o. Liver
topp. }Liver (m), lymphomas
p.o. Thyroid, pituitary
p.o. Liver
p.o. Lung
i.p. Lung, kidney
p.o. Liver
i.p. Lung, liver, ovary
i.h.
i.p. SLung, liver etc.
s.c. J
i.h. Lung, mammary
gland. liver
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Reference
87 6 (1974)
253 7 (1974)
183 4 (1974)
53 7 (1974)
113 13 (1977)
75 11 (1976)
319 16 (1978)
185 7 (1974)
193 9 (1975)
209 9 (1975)
107 1 (1972)
95 1 (1972)
135 1 (1972)
125 1 (1972)
179 6 (1974)
191 6 (1979)
99 6 (1974)
123 6 (1974)
157 13 (1977)
189 9 (1975)
2594 (1974)
67 7 (1974)
231 10 (1976)
245 10 (1976)
337 17 (1978)
85 7 (1974)
235 9 (1975)
111 7 (1974)
291 7 (1974)I. F. H. PURCHASE
3. Rat results (all p.o.) negative, mouse positive
Mouse
Compound Route ReferencE
1,4-Butanediol dimethane i.v.* 247 4 (1974
sulphonate
T E%-r%r DDT} p.O. 83 5 (1974)
Dieldrin p.o. 125 5 (1974)
Isonicotinic acidhydrazide s.c., 159 4 (1974)
i.p.,
P.O.
2-Naphthylamine p.o. 97 4 (1974)
Trichlorethylenel p.o. 263 11 (1976)
1 Trichloroethylene also included in NCI list.
IARC opinion based on early report ofNCI data.
* p.o. negative.
4. Rat results positive, mouse negative
Rat Mouse
Compound Route Route Reference
Daunomycin
p-Dimethylamino-
azobenzene
Thiourea
Aflatoxin BI
i.v. p.o. 145 10 (1976)
top., top. 125 8 (1975)
i.p.,
P.O.
P.O.
p.o. p.o.
P.O.
P.O.
95 7 (1974)
51 10 (1976)
5. Different results from various species
Compound
Arsenic compounds
Chlormadinone acetate
3,3'-Dimethylbenzidine
Hydrazine
Thioacetamide
Neg.
Species Route
Rat
Mouse P.O.
Rat
Mouse fP.O
Hamster p.o.
Hamster p.o.
Hamster p.o.
Pos.
Species Route
Man top.
Dog p.O.
Rat fs.c.
vi.p. Rat [p.o.
Mouse i i.p.
Lp.o. Rat
Mouse fP.O.
Routes: In addition to the usual abbreviations are the following:
p.o.-gavage or in diet.
top.-topical.
i.h.-inhalation.
i.pl.-intrapleural injection.
i.b.-intrabronchial pellets.
APPENDIX 3
Summarized carcinogenicity resultsfrom references derived from U.S. Public Health
ServicePublication No. 149
1. Compounds negative in both rat (R) and mouse (M) (excluding compounds in Appendix 2)
Compound M/R Route Reference
(Acetato) phenylmercury M i.vag. Boyland & Roe (1964) Br. Emp. Cancer Campaign,
42, 22.
R p.o. Fitzhugh et al. (1950) AMA Arch. Ind. Hyg., 2, 433.
Acetone M top. Roe et al. (1970) Br. J. Cancer, 24, 788.
R top.2 Glucksmann & Cherry (1968) Br. J. Cancer,22, 545.
Adipic acid dioctyl ester M top., S.C. Hodge et al. (1966)
Tox. Appl. Pharmacol., 9, 583.
Reference
48 2 (1973)
149 6 (1974)
87 1 (1972)
127 4 (1974)
77 7 (1974)
464
-
OC IE , .%_,Av
e
4)INTER-SPECIES COMPARISONS OF CARCINOGENICITY
Compound
Aniline (or aniline hydrochloride)
Anthracene
Arabinose
Arachis oil
Azobenzene
Benzene-1-azo-2-naphthol
Benzene hexachloride (y isomer)
Benzoyl peroxide
2-Biphenylol
3,6-Bis(dimethylamino)acridine
(Acridine Orange)
Camphor
Carboxymethylcellulose
2-Chloro-4,6-bis(ethylamino)-s-
triazine (Simazin)
Cholesterol
CI Acid Blue 9, diammonium salt
(Brillianlt Blue)
CI Acid Green 5, disodium salt
(Light Green SF Yellowish)
CI Acid Red 26, isodium salt
(Ponceaux MX)
CI Food Blue 1, disodium salt
(FD & C Blue No. 2)
CI Food Green 3, disodium salt
(Fast Green FCF)
CI Food Red 1, disodium salt
(Ponceaux SX)
CI Solvent Yellow 5
(phenylazo-2-naphthylamine)
CI Solvent Yellow 6 (I-(2-
methylphenyl)azo-2-
naphthalenamine)
Cyclohexanesulfanic acid,
monosodium salt
Cyclohexene hydroperoxide
D-glucose
2,6-Dichloro-4-nitroaniline
Dicyclohexylamine
3,3'-Dihydroxybenzidine
p-Diethylaminoazobenzene
17ox,21-Dihydroxypregn-4-ene-
3,11,20-trione (Cortisone)
M/R Route
M s.c.2
R p.o.
M s.c.
R s.c.2
M s.c.
R s.c.
M s.c.
R s.c.
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
s.c.2
S.C.
P.O.
p.o.2
top.
P.O.
P.O.
P.O.
P.O.
P.O.
S.C.
i.p., top.
S.C.
p.o.
P.O.
P.O.
.p.o.
s.c.
S.C.
i.p.,tp
s.c.
P.O.
P.O.
P.O.
P.O.
P.O.
s.c.
P.O.
P.O.
P.O.
P.O.
P.O.
s.c.2
S.C., p.o.
s.c.
S.C. p.o.
P.O.
P.O.
s.c.
s.c.
s.c.
s.C.
P.O.
s.c.
P.O.
s.c.
s.c.
s.c.2
s.c.2
s.c.
S.C.
Reference
Hartwell & Andervont, In Hartwell & Shubick (1951)
50.
Druckrey (1950) Arch. Exp. Path. Pharmakol., 210,
137.
Steiner (1955) CancerRes., 15, 632.
Schmahl (1955) Kreb8for8ch., 60, 697.
}Hueper (1965) Cancer Res., 25, 440.
Boyland & Sims (1967) Int. J. Cancer, 2, 500.
Carter et al. (1969) Fd. Cosmet. Tox., 7, 53.
Dickens & Jones (1964) Br. Emp. Cancer Campaign,
42, 141.
Dickens & Jones (1965) Br. J. Cancer, 19, 392.
Shear & Stewart (1941) In Hartwell & Shubick (1951)
Spitzetal. (1950) Cancer,3, 789.
Clayson et al. (1965) Br. J. Cancer, 19, 297.
Hackmann (1951) Krebsforsch., 57, 530.
Orr (1948) Nature, 162, 189.
Fitzhugh et al. (1950) J. Am. Pharm. Assoc.,40, 583.
}Sharrat et al. (1964)Fd. Co8met. Toxicol.,2, 527.
Innesetal. (1969)J. Natt CancerInst.,42, 1101.
Hodge et al. (1952) J. Pharmacol. Exp. Therap., 104,
202.
}Van Duuren et al. (1969) Br. J. Cancer, 23, 587.
Stoner et al. (1973) CancerRes., 33, 3069.
Graffietal. (1953) Arch Ge8chwulstfor8ch,5, 110.
Ezeyza (1952) Semana Med., 100, 663.
McElligott & Hurst (1968) Fd Coemet. Toxicol., 6, 449.
Teller et al. (1970) Cancer Res.,30, 179.
Innesetal. (1969) J. Natl CancerInst.,42, 1101.
Pliss & Zabezhinsky (1970) Vopr. Onkol., 16, 81.
Bischoff(1957)J. NatlCancerInst., 19, 977.
Koch (1963) Arzneimittelfor8chung, 13, 1116.
}Hansen et al. (1966) Tox. Appl. Pharmacol., 8, 29.
Hansen et al. (1966) Fd Cosmet. Toxicol., 4, 389.
Waterman & Lignac (1958) ActaPhysiolPharmacol.
Neerl., 7, 35.
Ikeda et al. (1966) Fd Cosmet. Toxicol., 4, 485.
Hansen et al. (1966) Tox. Appl. Pharmacol., 8, 29.
Hansen et al. (1966) Fd. Co8met. Toxicol., 4, 389.
Davis et al. (1966) Tox. Appl. Pharmacol., 8, 306.
2 }Hansen et al. (1963) Tox. Appl. Pharmacol., 5, 16.
20
Rudali et al. (1969) C. R. Acad.Sci.,269, 1910.
Grasso et al. (1971) Fd Co0met. Toxicol., 9, 463.
Van Duuren et al. (1966) J. Natl CancerInst., 37, 825.
Hueper (1965) CancerRes.,25, 440.
Inneset al. (1969)J. Natl CancerInst.,42, 1101.
Hadidian et al. (1968) J. Natl CancerInst.,41, 985.
}Pliss (1958) Vopr. Onkol.,4, 659.
Bonser et al. (1956) Br. J. Cancer, 10, 533.
Pliss (1961) Vopr. Onkol., 7, 33.
}Kirby (1947) CancerRes., 7, 333.
Della Porta et al. (1970) Tumori, 56, 121.
Field (1959) Cancer Res., 19, 870.
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Compound
a,a-Dimethylbenzyl hydro-
peroxide
o,o-Dimethyl- 1-hydroxy-2,2,2-
trichlorethylphosphonate
(Dipterex, Trichlorphon)
2-(2-(2-(dodecyloxy)ethoxy)ethoxy)
ethanol
3-(Dodecyloxy)-1,2-propanediol-
1-(hydrogen sulphate),
sodium salt
9,10-Epoxystearic acid
Ergosterol
Ethanol
(Ethylenebis(dithiocarbamato))
Manganese (Maneb)
(Ethylenebis(dithiocarbamato))
Zinc (Zineb)
Hexamethylenetetramine
(Urotropin)
4-Hydroxy-3-nitrobenzenearsonic
acid
Indole
Isopropyl-N-(3-chlorophenyl)
carbamate
Lactose
Lauroyl peroxide
Maltose
1-Naphthyl-N-methylcarbamate
(Crag Sevin)
N-dodecylguanidine acetate
N,N-diphenylnitrosamine
Ochratoxin A
Piperonyl butoxide
Piperonyl ether butoxide
Polyethylene glycols
Polyvinyl pyridine-n-oxide
Procaine penicillin
1,2-Propanediol (propylene
glycol)
Sorbose
Sucrose
Sulfosuccinic acid, 1,4-bis-
(2-ethylhexyl)ester, sodium salt
I. H. F. PURCHASE
M/R Route
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
R
Reference
s.c. Van Duuren et al. (1966) J. Natl Cancer4Inst.,37, 825.
s.c.2 Van Duuren et al. (1967) J. Natl Cancer Inst.,39,
1213.
top. Gibel et al. (1971) Arch. Geschwtvustforsch,37, 303.
s.c.
top. l
p.o. Tusing et al. (1962) Tox. Appl. Pharmacol., 4, 402.
top.
P.O.
s.C. Van Duuren et al. (1966) J. Natl Cancer Inst.,37, 825.
s.c.
top. Barry et al. (1935) Proc. R. Soc. Lond. [Biol.], 117,
318.
i.p.2 Pizzolato & Beard (1945) Exp. Med. Surg.,3, 95.
p.o. Kuratsune et al. (1971) Gann, 62, 395.
p.o.2 Yamamoto et al. (1967) Int. J. Cancer, 2, 337.
p.o. Innes et al. (1969) J. Natl Cancer Inst., 42, 1101.
p.o. Andrianova & Alekseev (1970) Vopr. Pitan.,29, 71.
p.o. Innes et al. (1969) J. Natl Cancer Inst., 42, 1101.
p.o. Smith et al. (1953) J. Pharmacol. Exp. Therap., 109,
159.
p.o. Della Porta et al. (1968) Fd C08met. Toxicot., 6, 707.
p.o. 2 Della Porta et al. (1970) Tumori, 56, 325.
p.O. Prier et al. (1963) Tox. Appl.Pharmacol., 5, 526.
s.C. Felistovich (1964) Vopr. Onkol., 10, 70.
p.o. McDonald et al. (1962) J. Urot., 87, 381.
p.o. 2 Innes et al. (1969) J. Natl CancerInst.,42, 1101.
p.o. Larson et al. (1960) Tox. Appl. Pharmacol., 2, 659.
sC. }Hueper (1965) CancerRes.,25, 440.
s.C. Vani Duuren et al. (1966) J. Natl Cancer Inst., 37, 825.
s.c.2 Van Duuren et al. (1967) J. Natl CancerInst.,39,
1213.
SC. }Hueper (1965) CancerRes.,25, 440.
p.o.2 Innes et al. (1969) J. Natl CancerInst.,42, 1101.
p.o. Andrianova & Alekseev (1970) Vopr. Pitan.,29, 71.
p.o. Innes et al. (1969) J. Natl Cancer Inst.,42, 1101.
p.o. Levinskas et al. (1961) Tox. Appi. Pharmacoi.,3, 127.
p.o. Innes et al. (1969) J. Nati Cancer Inst.,42, 1101.
i.p. Boyland et al. (1968) Eur. J. Cancer,4, 233.
s.c.2 Dickens & Waynforth (1968) Br. Emp. Cancer
Campaign,46, 108.
s.C., p.o.2 Purchase & Van der Watt (1971) Fd Casmet. Toxicol.,
9, 681.
p.o. Innes et al. (1969) J. Natl Cancer Inst.,42, 1101.
p.o. Sarles & Vandegrift (1952) J. Trop. Med. Hyg., 1, 862.
p.o.2 Innes etal. (1969) J. Natl Cancer Inst.,42, 1101.
p.o.2 Sarles & Vandergrift (1952) J. Trop. Med. Hyg., 1,
862.
p.o. Roe et al. (1970) Fd. Casmet. Toxicol., 8, 135.
i.p. Boyland et al. (1968) Eur. J. Cancer, 4, 233.
i. v . Schmahl (1969) Arzneimittelforschung, 19, 1313.
i.v.
im.4m FGilman & Ruckerbauer (1962) CancerRes.,22, 152.
top. Fujino et al. (1965) J. Natt Cancer Inst.,35, 907.
s.C. Hine et al. (1958) Arch. Ind. Hlth, 17, 129.
s.c.
S.c. Hueper (1965) CancerRes.,25, 440.
p.o. Klein (1963) Cancer Res.,23, 1701.
p.o. Fitzhugh & Nelson (1948) J.Pharmacol. Exp. Therap.,
93, 147.INTER-SPECIES COMPARISONS OF CARCINOGENICITY
Compound
Tricaprylin
1,1,1-Trichloro-2,2-bis(p-
methoxyphenyl)ethane
(methoxychlor)
M/R Route
M S.C.
R s.c.
M top.
R p.o.
Reference
}Van Duuren et al. (1966) J. Natl Cancer Inst.,37, 825.
Hodge et al. (1966) Tox. Appl. Pharmacol.,9, 583.
Deichmann et al. (1967) Tox. Appl. Pharmacol., 11, 88.
2. Compounds positive in both rat and mouse
Compound
2-Acetylaminofluorene
2-Amino-2,5-azotoluene
2-Amino-fluorene
2-Anthramine
Bis(acetato)dihydroxytri-
lead
Carbon tetrachloride
2,7-Diacetylaminofluorene
p-Dimethylaminobenzene-
1-azo-2-naphthalene
7,12-Dimethylbenz(a)-
anthracene
4'-Fluoro-4-aminodiphenyl
Imuran
3-Methylcholanthrene
7-Methylbenz(a)-
anthracene
N-Fluoren-2-yl
acetohydroxamic acid
N-Isopropyl-a-(2-methyl-
hydrazino)-p-toluamide
monochloride
N-nitrosobutylethylamine
N-nitrosobutylurea
M/R Route
M
R
M
R
M
R
M
R
M
R
M
R
M
R
M
P.O.
P.O.
P.O.
P.O.
top.
top.
top.
P.O.
P.O.
P.O.
P.O.
s.c.
P.O.
P.O.
top.
Affected Reference
organ
Liver, bladder Wood (1969) Eur. J. Cancer,5, 41.
Liver, Peraino et al. (1971) CancerRes.,31, 1506.
mammarygland
Liver I .-. _ _ n A n 7 T _- - _ - - -
Liver
Liver
Liver
Mammary gland
Skin
Kidney
Kidney, brain
Liver
Liver
Liver
Mammary gland,
liver, intestine
Skin
R p.o. Liver
M i.v. Leukaemia,
ovary
R i.v. Mammarygland
M p.o. Liver
R s.c. Kidney, liver
M i.m. Thymus etc.
R p.o. Zymbal gland
M top., s.e. Leukaemia,
local
R p.o., s.c. Mammarygland,
local
M
R
M
R
M
R
M
R
M
R
s.c.
P.O.
P.O.
I.p.
I.p.
P.O.
P.O.
P.O.
P.O.
Local
Local
Mammary gland,
stomach, liver
Liver, bladder
Leukaemia, lung
Mammary gland
Stomach
Oesophagus
Thymus,
leukaemia
Zymbal gland
CJrabtree (I1948) Br. J. Cancer,3, 387.
Bielschowsky & Bielschowsky (1960) Br. J.
Cancer, 14, 195.
Goodall (1965) Endocrinology, 76, 1027.
Lennox (1955) Br. J. Cancer,9, 631.
Griswold et al. (1968) CancerRes.,28, 924.
Van Esch & Kroes (1969) Br. J. Cancer,23,
765.
Oyaswi etal. (1970) CancerRes.,30, 1249.
Unakar (1966) Arch.Path.,82, 170.
Reuber & Glover (1970) J. Natl CancerInst.,
44, 419.
Takayama (1968) J. Natl CancerInst.,40,
629.
Yamada et al. (1971) Gann., 62, 471.
Mulay & Saxen (1952) J. Natl CancerInst.,
13, 1259.
Mulay & Longdon (1953) J. Natl Cancer
Inst., 14, 571.
Uematsu & Higgins (1969) Gann.,60,545.
Geyer et al. (1953) CancerRes., 13, 503.
Clayson et al. (1965) Br. J. Cancer, 19, 297.
Matthews & Walpole (1958) Br. J. Cancer,
12, 234.
Casey (1968) Blood,31, 396.
Frankel et al. (1970) Tox. Appl.Pharmacol.,
17, 462.
Rubin (1971)Progr. Exp. TumorRes., 14,
138.
Matsuyama et al. (1963) Nature, 197, 805.
Gruenstein et al. (1966)J. NatlCancerInst.,
36, 483.
Matsuyama et al. (1963) Nature, 197, 805.
Miller & Miller (1963) CancerRes.,23, 229.
Pataki & Huggins (1969) CancerRes.,29,
506.
Millei et al. (1964) CancerRes., 24, 2018.
Weisburger et al. (1970) J. Natl CancerIn8t.,
45, 29.
Kelly et al. (1969) J. Natl Cancer In8t., 42,
337.
Kelly et al. (1968) J. Natl CancerIn8t.,40,
1027.
Schmahl et at. (1963) Naturwi8senschaften,
50, 717.
Thomas & So (1969) Arzneimittelforschung,
19, 1077.
Yokoro et al. (1970) Gann, 61, 287.
Odashima (1970) G'ann.,61, 245.
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Compound M/R Route Affected
organ
N-nitrosomethylaniline
N-4-((5-Nitro-2-furyl)-2-
thiazolyl)formamide
3-Nitro-3-hexene
4-Nitroquinoline 1-oxide
4-Nitrosopiperazine
19-Nor-l17a-pregn-
1,3,5(10)-trien-20-yne-
3,17-diol
M
R
M
R
M
R
M
R
M
R
M
P.O.
P.O.
P.O.
P.O.
inh.
inh.
s.c.
s.c.
P.O.
P.O.
P.O.
R p.o.
Lung, lympho- Greenblatt et al. (1971) J. Nati Cancer In8t.,
reticular 46, 1029.
Lymphoreticular, Goodall et al. (1970) Tox. Appl. Pharmacol.,
stomach 17, 426.
Bladder Erturk et al. (1970) Cancer Res.,30, 1309.
Bladder Erturk et al. (1969) Proc. Am. Assoc. Cancer
Res., 10, 23.
Lung Deichmann et al. (1965) Indus. Med. Surg.,
Lung J 34, 800.
Lung Mori et al. (1966) Gann., 57, 559.
Lung
Lung Greenblatt et al. (1971) J. Natl CancerIn8t.,
46, 1029.
Lymphoreticular Garcia et al. (1970) Z. Krebsfor8ch, 74, 179.
Mammary,
1 Committee on Safety of Medicines (1972) uterine * Carcinogenicity tests oforal
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3. Rat results negative; mouse positive
Compound
6-Aminochrysene
1,1-Dimethylhydrazine
M/R Route
M top.
R p.o.2
M p.o.
R p.o.
Reference
Lambelin et al. (1975) Eur.J. Cancer, 11, 327.
Higgins (1964) Proc. NatlAcad. Sci., 51, 737.
Toth (1972) Proc. Am. Assoc. CancerRes., 13, 34.
Argus & Hoch-Ligeti (1961) J. Natl Cancer In8t., 27,
695.
4. Rat results positive; mouse negative
Compound
4-Aminostilbene
Oestrone
Poly(1,2-dihydro-2,2,4-
trimethyl-quinoline)
Polyethyleneglycol monostearate
4-Styrylacetanilide
M/R Route Reference
M p.o. Clayson et al. (1965) Br. J. Cancer, 19, 297.
R p.o.2 Anderson et al. (1964) CancerRes.,24, 128.
M p.o. Biancifiori et al. (1967) Br. J. Cancer,21, 452.
R s.c. Cutts (1964) Cancer Res.,24, 1124.
S.c., top. }Hodge et al. (1966) Tox. Appl. Pharmacol., 9, 583.
R p.o.
M p.o. Hueper & Payne (1963) Arch. Env. Hlth, 6, 484.
R p.o.
M p.o. Clayson et al. (1965) Br. J. Cancer, 19, 297.
R p.o. Baldwin et al. (1968) Br. J. Cancer,22, 133.
Footnote
1 Data not quoted by IARC Monograph Vol. 4, p. 137.
2 Animal group sizes relatively small.
Routes abbreviated as follows:
p.o. gavage or addition to diet.
top.-topical application.
i.vag.-intravaginal instillation.
Reference
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